Package Leaflet: Information for the Patient
Isturisa 1 mg film-coated tablets
Isturisa 5 mg film-coated tablets
Isturisa 10 mg film-coated tablets
osilodrostat
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Isturisa
Isturisa is a medicine that contains the active substance osilodrostat.
What Isturisa is used for
Isturisa is used to treat endogenous Cushing's syndrome in adults, a disease in which the body produces too much of a hormone called cortisol. Excess cortisol can cause a variety of symptoms such as weight gain (especially around the waist), a moon-shaped face, easy bruising, irregular periods, excess hair on the body and face, and generally a feeling of weakness, fatigue or malaise.
How Isturisa works
Isturisa blocks the main enzyme that produces cortisol in the adrenal glands. The effect is a decrease in the overproduction of cortisol and an improvement in the symptoms of endogenous Cushing's syndrome.
Do not take Isturisa:
Warnings and precautions
Consult your doctor or pharmacist before taking Isturisa.
If you are in any of the following situations, inform your doctor before taking Isturisa:
Contact your doctor immediately if you have two or more of these symptoms during treatment with Isturisa. This may indicate that you have adrenal insufficiency (low cortisol levels):
These symptoms may continue for months after stopping treatment with Isturisa. Contact your doctor as you may need treatment and/or additional monitoring.
Checks before and during treatment
Your doctor will perform blood and/or urine tests before starting treatment and regularly during treatment. This is to detect any possible changes in magnesium, calcium, and potassium levels and also to measure cortisol levels. Depending on the results, your doctor may change the dose you take.
This medicine may have an unwanted effect (called QT prolongation) on the heart. Your doctor will therefore also check this effect by performing an electrocardiogram (ECG) before starting treatment and during treatment.
If your Cushing's syndrome is due to a benign tumor (called an adenoma) in the pituitary gland, your doctor may consider stopping treatment if the pituitary gland scan shows that the adenoma has expanded into surrounding areas.
Children and adolescents
This medicine is not recommended for patients under 18 years of age. This is due to the lack of data in these patients.
Other medicines and Isturisa
Tell your doctor if you are taking, have recently taken, or might take any other medicines. It is especially important that you mention any of the following medicines:
Pregnancy and breastfeeding
This medicine must not be used during pregnancy and breastfeeding unless your doctor has told you to do so. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Contraception
Women who can become pregnant must use an effective contraceptive method during treatment and for at least one week after the last dose. Consult your doctor about the need for contraception before starting treatment with Isturisa.
Driving and using machines
Dizziness and fatigue may occur during treatment with Isturisa. Do not drive or use machines if you have these symptoms.
Isturisa contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as told by your doctor.
In case of doubt, consult your doctor or pharmacist again.
The usual starting dose is two 1 mg tablets twice a day (approximately every 12 hours). Patients of Asian origin and patients with liver disease may need a lower starting dose (one 1 mg tablet twice a day).
After starting treatment, your doctor may change the dose. This will depend on how you respond to treatment. The highest recommended dose is 30 mg twice a day.
Isturisa tablets are taken orally and can be taken with or without food.
If you take more Isturisa than you should
If you have taken more Isturisa than you should and do not feel well (for example, you feel weak, dizzy, tired, nauseous, or have vomiting), or if someone else has taken your medicine by mistake, contact a doctor or hospital immediately. You may need medical treatment.
If you forget to take Isturisa
Do not take a double dose to make up for forgotten doses. Instead, wait until the time of the next dose and take it when it is due.
If you stop taking Isturisa
Do not stop taking Isturisa unless your doctor tells you to. If you stop taking Isturisa, the symptoms may come back.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects may be serious.Pay special attention to the following:
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
Do not store above 25°C.
Store in the original package to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Isturisa contains
Appearance of Isturisa and pack contents
Isturisa is available in packs containing 60 film-coated tablets.
The 1 mg tablets are light yellow, round, not scored, and have a "1" engraved on one side. The approximate diameter is 6.1 mm.
The 5 mg tablets are yellow, round, not scored, and have a "5" engraved on one side. The approximate diameter is 7.1 mm.
The 10 mg tablets are light orange-brown, round, not scored, and have a "10" engraved on one side. The approximate diameter is 9.1 mm.
Marketing authorisation holder
Recordati Rare Diseases
Tour Hekla
52 avenue du Général de Gaulle
92800 Puteaux
France
Manufacturer
Millmount Healthcare Ltd
Block 7, City North
Business Campus, Stamullen,
Co. Meath, K32 YD60,
Ireland
Recordati Rare Diseases
Tour Hekla
52 avenue du Général de Gaulle
92800 Puteaux
France
Recordati Rare Diseases
Eco River Parc
30 rue des Peupliers
92000 Nanterre
France
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Belgium Recordati Tel: +32 2 46101 36 | Lithuania Recordati AB. Tel: + 46 8 545 80 230 Sweden |
Luxembourg Recordati Tel: +32 2 46101 36 Belgium | |
Czech Republic Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Hungary Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Denmark Recordati AB. Tel: + 46 8 545 80 230 Sweden | Malta Recordati Rare Diseases Tel: +33 1 47 73 64 58 France |
Germany Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 | Netherlands Recordati Tel: +32 2 46101 36 Belgium |
Estonia Recordati AB. Tel: + 46 8 545 80 230 Sweden | Norway Recordati AB. Tel: + 46 8 545 80 230 Sweden |
Greece Recordati Hellas Tel: +30 210 6773822 | Austria Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 Germany |
Spain Recordati Rare Diseases Spain S.L.U. Tel: + 34 91 659 28 90 | Poland Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
France Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 | Portugal Recordati Rare Diseases SARL Tel: +351 21 432 95 00 |
Croatia Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Romania Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Ireland Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Slovenia Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Iceland Recordati AB. Tel: + 46 8 545 80 230 Sweden | Slovakia Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Italy Recordati Rare Diseases Italy Srl Tel: +39 02 487 87 173 | Finland Recordati AB. Tel: +46 8 545 80 230 Sweden |
Cyprus Recordati Rare Diseases Tel: +33 1 47 73 64 58 France | Sweden Recordati AB. Tel: +46 8 545 80 230 |
Latvia Recordati AB. Tel: + 46 8 545 80 230 Sweden |
Date of last revision of this leaflet:12/2024
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu